Massimo Mischi is a Full Professor at the Faculty of Electrical Engineering of the Eindhoven University of Technology (TU/e) and chairs the Signal Processing Systems (SPS) Division , the largest division at TU/e with over 250 researchers. He founded the Biomedical Diagnostics (BM/d) Lab in 2012, which now includes 180 researchers and clinical/industrial advisors, focusing on biomedical signal processing for diagnostics and monitoring.
Sunitha Nagrath is a Professor of Chemical Engineering at the University of Michigan, leading the Nagrath Lab. Her research focuses on developing microfluidic and nanotechnology-based tools to isolate and analyze circulating tumor cells (CTCs) and extracellular vesicles (EVs) for cancer diagnostics and personalized medicine. She holds an AIMBE Fellowship and has pioneered technologies like the Graphene Oxide Chip and Microfluidic Labyrinth. Education PhD in Mechanical Engineering, Rensselaer Polytechnic Institute (2004) MS in Nuclear Engineering, Rensselaer Polytechnic Institute (2000) B.Tech in Chemical Engineering, Sri Venkateswara University (1992) Research Interests Her lab integrates engineering, biology, and clinical expertise to study CTCs' role in metastasis, develop high-throughput isolation methods, and leverage exosomes as liquid biopsy biomarkers. Key projects include: CTC-based monitoring of therapy response in lung and pancreatic cancers Microfluidic devices for simultaneous CTC and exosome analysis Functional studies of CTC-derived organoids for drug sensitivity testing Notable Achievements AIMBE Fellow (Junior Faculty, Harvard Medical School/MGH, 2008-2010) Over 150 peer-reviewed publications and patents on CTC/exosome technologies Recipient of the 2021-22 Chemical Engineering Staff Incentive Award (via lab member Mina Zeinali) Labs & Collaborations The Nagrath Lab collaborates with clinicians and engineers to translate technologies like the OncoBean Chip and EVOD chip into clinical settings. Current work emphasizes real-time CTC monitoring and exosome-based immuno-oncology strategies.
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Ruth Keogh is a Professor of Biostatistics and Epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM), affiliated with the Medical Statistics Department within the Faculty of Epidemiology and Population Health. She is Co-Director of the Centre for Data and Statistical Science for Health (DASH) and serves as Departmental Research Degrees Coordinator. Her academic career has spanned roles from Lecturer (2012–2015) to Associate Professor (2015–2019) before attaining her current rank in 2019. Keogh holds advanced degrees including a DPhil in Medical Statistics/Epidemiology (University of Oxford, 2007), MSc in Applied Statistics (Oxford, 2003), and BSc in Mathematics and Statistics (University of Edinburgh, 2002). Her research focuses on causal inference, clinical trial emulation using real-world data, and applications in cystic fibrosis, infectious diseases, and public health. She leads projects on lung function trajectories, vaccine efficacy, and healthcare policy analysis. Her work integrates biostatistical methods with epidemiological studies, emphasizing rigorous analysis of observational data to inform clinical decisions. Notable areas include evaluating antibiotic treatments for cystic fibrosis patients, assessing diagnostic test accuracy for dengue and leptospirosis, and modeling vaccine effectiveness during the COVID-19 pandemic. She teaches courses in survival analysis, electronic health records, and health data science at LSHTM. Keogh has held leadership roles in the International Biometric Society and the STRATOS Initiative, and she has delivered keynote addresses at international conferences on trial emulation and biostatistical methods. Her contributions bridge methodological innovation and practical health challenges, with over 190 publications and active engagement in global health research networks.
Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.
Mike Kirby is a Professor at the Kahlert School of Computing, University of Utah. He also holds adjunct professorships in the Department of Bioengineering and the Department of Mathematics. His current roles include leadership in scientific computing and informatics initiatives, including former directorships of the Utah Informatics Initiative (2019-2023) and the Multi-Scale Multidisciplinary Modeling of Electronic Materials (MSME) Collaborative Research Alliance (2016-2022). He has extensive experience in strategic research initiatives, including serving as Assistant Vice President for Research (2024-2025). Education: Dr. Kirby earned a PhD in Applied Mathematics (2002) and MS in Computer Science (2001) from Brown University, and a BS in Applied Mathematics and Computer Science from Florida State University (1997). Research Interests: Focus on large-scale scientific computing, physics-informed machine learning, computational science and engineering, high-order numerical methods, and visualization. His work bridges applied mathematics and computer science to address real-world engineering challenges. Publications: Over 150 peer-reviewed articles, including high-impact contributions in journals like Journal of Computational Physics and SIAM Journal on Scientific Computing . Recent work emphasizes machine learning for differential equations, topology optimization under uncertainty, and multi-fidelity modeling. Awards: Recognized for leadership in computational science and informatics, including contributions to University of Utah’s Clery Compliance Program. Advising & Grants: Supervised over 50 graduate students and postdocs. Secured funding from NSF, DOE, and industry partnerships, totaling millions in research grants. Active in interdisciplinary collaborations across engineering, materials science, and medicine. Labs/Teams: Scientific Computing and Imaging (SCI) Institute, Utah Informatics Initiative, and the Center for Multiscale Modeling of Electronic Materials (MSME).
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Joseph P. Bressler is an Associate Professor at Johns Hopkins University, jointly affiliated with the Bloomberg School of Public Health and the Krieger School of Arts and Sciences. He is a member of the Department of Environmental Health and Engineering and conducts research at the Kennedy Krieger Institute in Baltimore, Maryland. His work bridges public health, neuroscience, and molecular toxicology, focusing on environmental impacts on brain development. Education: PhD, Rutgers University, 1978 Dr. Bressler’s research centers on neurotoxicology, particularly how environmental pollutants such as lead, cadmium, and aluminum disrupt metal transport systems and affect neurodevelopment. His laboratory investigates the role of iron and other metal transporters at the blood-brain barrier and in glial cells, revealing mechanisms of metal uptake and toxicity. His work has implications for understanding autism, fetal alcohol syndrome, and other neurodevelopmental disorders. His recent publications highlight ongoing research into metal homeostasis, cytotoxicity in cancer and neuronal cell lines, e-cigarette aerosol variability, and epigenetic changes in sex chromosome aneuploidies. The research spans molecular mechanisms, in vitro models, and human health outcomes, demonstrating a multidisciplinary approach to environmental health. Scientific Contributions: Elucidated how lead and cadmium hijack iron transporters to enter the brain Demonstrated aluminum activation of iron uptake pathways in glial cells Investigated flavoring agents like ethyl maltol in enhancing metal toxicity Explored epigenetic and behavioral impacts in rare genetic conditions Dr. Bressler has advised numerous researchers and collaborators across disciplines. His work has been supported by federal and institutional grants, though specific funding details are not provided in the source text. He actively publishes in high-impact toxicology and environmental health journals, with research cited in policy and public health discussions. He leads a research laboratory focused on cellular and molecular mechanisms of neurotoxicity, utilizing in vitro models of the blood-brain barrier, astrocytes, and neuronal cell lines. His team collaborates widely across neuroscience, public health, and environmental engineering domains.
Prof. Abbas Samani is a Professor at the Department of Electrical and Computer Engineering and holds a joint appointment in the Department of Medical Biophysics at Western University . He is a core faculty member of the Biomedical Engineering Graduate Program and an Associate Scientist at Imaging Research Laboratories of Robarts Research Institute . His academic journey includes a Ph.D. from the University of Waterloo, an M.Sc. from the University of Tehran, and a B.Sc. from Amirkabir University of Technology. His research focuses on biological tissue computational modeling and its applications in medical imaging, intervention, and image analysis . He develops computer/image-assisted tools for minimally invasive disease diagnosis and therapy , targeting heart disease, cancer, and lung disease . Key projects include myocardium biomechanical modeling , handheld medical devices for breast cancer screening , and lung disease diagnostics via CT image segmentation . His recent publications emphasize ultrasound elastography , finite element modeling , and inverse problems in biomechanics , primarily in journals like IEEE Transactions on Computational Imaging and Translational Oncology . His work spans both computational modeling and medical device development . Selected Graduate Supervision : Ph.D. Candidates : Seyed Hassan Haddad, Elham Karami, Seyed Mohammad Hesabgar Graduated Ph.D. Students : Ali Sadeghi Naini, Seyed Reza Mousavi M.Sc. Students : Cristian Linte, Patrick Courtis, Joseph O'Hagan, Hatef Mehrabian, Hirad Karimi, Hosein Amooshahi, Seyed Mohammad Hesabgar, Nastaran Ghadarghadr, Shadi Shavakh, Ehsan Salamati, Ehsan Omidi Teaching Contributions : Graduate: BME9519B/CAMI9519B/ECE9202B/ECE9022B - Advanced Image Processing and Analysis , MBP9530A - Human Biomechanics and Biomedical Applications Undergraduate: ECE4438B - Advanced Image Processing and Analysis , ES1050 - Introductory Engineering Design and Innovation Studio , MBP3330F - Human Biomechanics and Biomedical Applications Research Affiliations : Robarts Research Institute - Associate Scientist at Imaging Research Laboratories Western University - Core Faculty, Biomedical Engineering Graduate Program
Lawrence Staib is Professor of Radiology and Biomedical Imaging, Biomedical Engineering, and Electrical Engineering at Yale University. He serves as Director of Undergraduate Studies in Biomedical Engineering and is a member of Yale's Bioimaging Sciences division, Image Processing & Analysis Group, Yale Biomedical Imaging Institute, and Yale-BI Biomedical Data Science Fellowship program. Dr. Staib earned his A.B. in Physics from Cornell University (1982), followed by a Ph.D. in Engineering and Applied Science from Yale University (1990), and completed a postdoctoral fellowship at Yale School of Medicine (1991). His research focuses on developing advanced medical image analysis methods using machine learning and model-based approaches. Key research areas include neuroimaging applications for autism spectrum disorder classification, cardiac imaging analysis for strain and motion assessment, prostate cancer diagnosis and risk mapping, and innovative techniques for medical image segmentation with limited labeled data. Dr. Staib's work emphasizes uncertainty estimation in deep learning models, multi-modal image registration, and domain adaptation techniques to improve clinical decision support systems. His recent publications demonstrate a strong trend toward developing interpretable AI models for clinical applications, with particular emphasis on fMRI analysis for neurological conditions, cardiac motion analysis, and prostate cancer diagnosis. His work frequently addresses the challenge of limited labeled data in medical imaging through innovative self-supervised, semi-supervised, and few-shot learning approaches. Fellow of the American Institute for Medical and Biological Engineering (AIMBE) (2015) Distinguished Investigator Award from the Academy for Radiology & Biomedical Imaging Research (2017) MICCAI Fellow (2022) Medical Image Analysis Second Best MICCAI Paper Award (2005) ASNR Cum Laude Scientific Exhibit Award (2003) Dr. Staib serves on the editorial board of Medical Image Analysis and as Associate Editor of IEEE Transactions on Biomedical Engineering. His research is supported by NIH grants including the Autism Center of Excellence program. He leads the Image Processing & Analysis Group within Yale's Bioimaging Sciences division, collaborating extensively with James Duncan, John Onofrey, Xenophon Papademetris, and other Yale researchers on applications spanning neuroimaging, cardiology, and oncology. Current projects focus on developing robust AI models for clinical decision support with emphasis on uncertainty quantification and interpretability.
Yu He is an Assistant Professor of Applied Physics and Physics at Yale University, affiliated with the Department of Physics. His research focuses on condensed matter physics and experimental techniques such as angle-resolved photoemission spectroscopy (ARPES) and x-ray scattering to study correlated electronic systems and quantum materials. Prior to Yale, he completed a Miller Research Fellowship at UC Berkeley (2019) after earning his Ph.D. in Applied Physics from Stanford University. Key research areas include metal-to-insulator transitions, superconductivity, 2D magnetism, and solid-state quantum simulation. He has contributed to advancements in material characterization techniques, including high-resolution ARPES using tabletop lasers. His work integrates crystal synthesis, electric transport measurements, and surface decoration to explore material properties. Education: B.S. in Physics from University of Science and Technology of China (USTC); M.S. in Electrical Engineering and Ph.D. in Applied Physics from Stanford University. Research Interests: Experimental condensed matter physics, quantum materials, superconductivity, and light-matter interaction studies. His current projects aim to dissect microscopic degrees of freedom (electronic, lattice, spin) in novel materials using cutting-edge spectroscopic methods. The lab employs complementary techniques like electric transport measurements and crystal growth to characterize material properties comprehensively. Awards: Miller Research Fellow, UC Berkeley (2019) Advising & Grants: No student advisees listed. Research supported by Yale University and prior fellowships. Labs & Teams: Leads a research group at Yale focused on experimental condensed matter physics, collaborating on projects involving advanced material characterization and quantum material discovery.
Dr. Jason Webber is a Senior Lecturer in Biomedical Sciences at Swansea University Medical School. He holds an honorary position as a Research Fellow at Cardiff University and is a board member of the UK Society for Extracellular Vesicles. His research focuses on extracellular vesicles (EVs), particularly their role in cancer progression and as biomarkers for aggressive tumors like prostate cancer. He completed his PhD at Cardiff University's Institute of Nephrology in 2009 and received a Prostate Cancer UK Career Development Fellowship (2014–2020). Dr. Webber's expertise includes EV biology, tumor microenvironment dynamics, and translational research. He actively contributes to teaching modules such as 'Genetics of Cancer' and 'Advanced Research Topics in Biomedical Science'. His work spans collaborations with institutions like Erasmus MC and the CIC bioGUNE in Spain. Key grants include funding for projects like 'Extracellular Vesicle Glycoproteins for Prostate Cancer Diagnosis (EVGlyProD)' and investigations into EV roles in bone metastasis and rare diseases like tuberous sclerosis complex. His research highlights EVs' dual role as functional mediators of tumor growth and potential biomarkers. Notable achievements include demonstrating EV-HSPG's role in stromal activation and developing methodologies for EV-based diagnostics. Dr. Webber supervises multiple PhD and MSc students, emphasizing mentorship in EV research and cancer biology.
Tom Stargardt is a Professor of Health Care Management at the Hamburg Center for Health Economics, University of Hamburg. His research focuses on health economics, pharmaceutical policy, and healthcare system efficiency. He holds a Dr. rer. oec. from TU Berlin (2008) and has held academic positions including Junior Professor for Pharmacoepidemiology at the University of Hamburg and a postdoctoral fellowship at LMU Munich and Helmholtz Zentrum München. His work spans cost-effectiveness analyses of treatments, health technology assessment, and pandemic-related behavioral economics. He has been recognized with the 2009 Nachwuchspreis for health economics/politics and a 2007 Merck-funded stipend. Research interests include pharmaceutical market dynamics, telemedicine cost-benefit analyses, and socioeconomic disparities in healthcare access. He has authored over 100 publications on topics like drug pricing regulations, vaccine hesitancy, and pandemic policy responses. His current projects analyze healthcare system efficiency during crises and the impact of digital health interventions. He is affiliated with the Hamburg Center for Health Economics and serves on editorial boards for journals like Pharmacoeconomics and Health Economics. Educations: TU Berlin (PhD 2008, Diplom 2005) Key Awards: Progenerika Early Career Prize (2009), Merck Stipend (2007) Professional Memberships: Verein für Socialpolitik, International Health Economics Association His advisory work includes evaluations of disease management programs and health policy reforms. Recent grants focus on pandemic healthcare economics and biosimilar market dynamics. He leads research teams investigating cost-utility of innovative cancer therapies and digital health solutions for chronic disease management.
Raegan Higgins is a Professor and Associate Vice Provost for Faculty Success at Texas Tech University's Department of Mathematics & Statistics. She earned her BS from Xavier University of Louisiana and MS/PhD from the University of Nebraska, focusing on time scales calculus. Her research spans oscillation criteria for dynamic equations, mathematical biology, and STEM education equity. She has led initiatives like the Bridges Across Texas LS-AMP program to support underrepresented students in mathematics. Higgins has received awards including the Gweneth Humphreys Award for Mentoring (2021) and was recognized as a Top 20 Under 40 by the Lubbock Chamber of Commerce (2019). She teaches advanced mathematics courses and has mentored numerous graduate students in areas like prostate cancer modeling and calculus curriculum reform. Her educational history includes a Bachelor of Science in Mathematics (Xavier University) and advanced degrees from the University of Nebraska, with an emphasis on time scales. Higgins actively engages in outreach through organizations like the Association for Women in Mathematics and the Infinite Possibilities Conference, promoting diversity in STEM. She has secured NSF grants totaling millions to support teacher training, minority participation, and undergraduate research experiences. Key research themes include time scales applications in biological models and improving mathematics teaching practices. Higgins' work bridges academia and community through programs like the South Plains Mathematics Fellows and the West Texas Middle School Math Partnership. Her articles address oscillation theory, STEM retention strategies, and interdisciplinary approaches to mathematics education.
Hong Han is an Assistant Professor in the Department of Biochemistry & Biomedical Sciences within McMaster University's Faculty of Health Sciences and a member of the Centre for Discovery in Cancer Research (CDCR). She holds a Canada Research Chair and leads the Han Lab, which focuses on cancer biology, RNA regulation, and innovative high-throughput technologies for therapeutic discovery. Dr. Han earned her Ph.D. from the University of Toronto (2010-2016) and has established herself as a leading researcher in glioblastoma and alternative splicing regulation. Her interdisciplinary research integrates cancer biology, RNA science, and multilayer gene regulation to uncover mechanisms underlying cancer progression and treatment resistance. Her laboratory pioneers integrated technological platforms for large-scale genetic/drug screening and ultra-high-throughput single-cell profiling. The research focuses on three main areas: alternative splicing regulation in cancer (particularly glioblastoma and prostate cancer), multilayer mechanisms of glioblastoma heterogeneity and microenvironment evolution, and multiplexed screening approaches for therapeutic discovery in treatment-resistant cancers. Analysis of Dr. Han's recent publications reveals a strong emphasis on single-cell technologies to characterize glioblastoma heterogeneity, minimal residual disease states, and tumor-immune interactions. Her work increasingly bridges basic RNA biology with translational applications, particularly in developing novel therapeutic strategies targeting splicing networks and immune evasion mechanisms. Canada Research Chair Dr. Han teaches Advanced Techniques in the Biomedical Sciences (BIOCHEM 734). Her research program is supported by multiple funding sources, as evidenced by her extensive publication record in high-impact journals including Nature, Cell, Molecular Cell, and Nature Communications. She employs a comprehensive approach combining in vitro, in vivo, and patient cohort studies with cutting-edge genomic technologies. The Han Lab has developed innovative multiplexed screening platforms that enable simultaneous interrogation of thousands of conditions, ranging from CAR-T cells to small molecule therapeutics. This approach accelerates the discovery of novel cancer targets and therapeutic strategies for treatment-resistant cancers.